KRAS and pancreatic neoplasm: While preclinical efficacy from afatinib in pancreatic cancer has been suggested to correlate with EGFR/HER2/HER3 expression and occurred irrespective of KRAS status [43], disease stabilizations seen in KRASMUT tumors in our study may have been solely due to capecitabine chemotherapy.